Cytotoxic activity of ribonucleolytic toxin restrictocin-based chimeric toxins targeted to epidermal growth factor receptor  by Rathore, Dharmendar & Batra, Janendra K
FEBS 18478 FEBS Letters 407 (1997) 275-279 
Cytotoxic activity of ribonucleolytic toxin restrictocin-based chimeric 
toxins targeted to epidermal growth factor receptor 
Dharmendar Rathore, Janendra K. Batra* 
Immunochemistry Laboratory, National Institute of Immunology, Aruna Asaf Ali Road, New Delhi 110067, India 
Received 3 March 1997 
Abstract Targeted toxins represent a new approach to specific 
cytocidal therapy. The ribonucleolytic protein toxin restrictocin 
is a potent protein synthesis inhibitor produced by the fungus 
Aspergillus restrictus. In the present study we have constructed 
two restrictocin based chimeric toxins where human transforming 
growth factor alpha (TGFcc) has been used as a ligand. TGFoc is 
a single chain polypeptide, which binds to epidermal growth 
factor receptor (EGFR) and causes proliferation in a large 
number of cancers. The ligand has been separately fused either at 
the amino terminus or carboxyl terminus of restrictocin, giving 
rise to TGFcc-restrictocin and restrictocin-TGFa respectively. 
The fusion proteins were overexpressed in Escherichia coli and 
purified from inclusion bodies by a denaturation-renaturation 
protocol. Both the chimeric toxins actively inhibited eukaryotic 
protein synthesis in a cell free in vitro translation assay system. 
These chimeric toxins selectively killed human epidermal growth 
factor receptor positive target cells in culture. Among the two 
proteins, restrictocin-TGFa was more active than TGFoc-
restrictocin on all the cell lines studied. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
One approach to cancer treatment that has received consid-
erable attention in the past few years is to direct protein 
toxins to cancer cells [1,2]. Toxins have been genetically fused 
to antibodies and growth factors to generate recombinant 
immunotoxins or chimeric toxins that can selectively kill cells 
bearing specific receptors or antigens [1,2]. The potent inhib-
itory activity of bacterial toxins like Pseudomonas exotoxin 
(PE) and diphtheria toxin (DT) as well as the plant toxin ricin 
has been exploited for making chimeric toxins [1^4-]. The 
choice of both the toxin and the target is extremely important 
in the construction of immunotoxins. An ideal target is either 
unique to the malignancy or is present in a large excess on the 
diseased cells to be eliminated [1], Chimeric toxins have been 
made using a variety of ligands such as transforming growth 
factor alpha (TGFoc), interleukin 2, interleukin 4, CD4, and 
single chain antibodies [1,2,4]. TGFoc is a mitogenic polypep-
tide of 50 amino acids and has structure and biological prop-
erties similar to that of epidermal growth factor (EGF) [5]. 
Both TGFa and EGF bind to subdomain III of the extrac-
ellular portion of epidermal growth factor receptor (EGFR), 
causing receptor autophosphorylation and initiation of a cas-
cade of biochemical reactions that ultimately leads to DNA 
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synthesis and cell division [6,7]. Elevated expression of EGFR 
is a characteristic of several malignancies including those of 
breast, bladder, prostate, lung, cervical, thyroid, esophageal 
and ovarian origin [8]. The EGF receptor contains a specific 
internalization sequence which contributes to the rapid inter-
nalization of the ligand receptor complex. Overexpression on 
various cancers and rapid internalization of the EGFR makes 
this receptor a good target for the selective delivery of anti-
cancer agents [8]. The factors that influence the potency of 
immunotoxins in cancer therapy are their specificity, cytotox-
icity, tumor penetration, toxicity and immunogenicity [1,4]. 
Though highly potent and specific immunotoxins have been 
made, the toxicity and immunogenicity of these molecules has 
limited their application [2]. Studies are now focused on en-
gineering the molecules further to resolve these issues. In ad-
dition, it would be helpful if new toxin molecules with low 
non-specific toxicity and immunogenicity are discovered, that 
can be used in the construction of chimeric toxins [1,2]. 
Ribotoxins are ribosome inactivating proteins produced by 
Aspergillus, that cleave a single phosphodiester bond on the 3' 
side of G4325 in eukaryotic 28S rRNA [9]. The cleavage site is 
embedded in a purine rich single stranded segment of 14 nu-
cleotides called the sarcin/ricin loop, which is one of the most 
strongly conserved regions of rRNA. Cleaved 28 S rRNA is 
unable to participate in EF-1 dependent binding of aminoacyl 
tRNA and EF-2 catalyzed GTP hydrolysis and translocation 
during protein synthesis, leading to cell death [10]. Restricto-
cin, one of the members of the ribotoxin family, is a 149 
amino acid single chain non-glycosylated polypeptide and a 
potent inhibitor of translation [11]. Restrictocin cannot enter 
into a cell on its own, and needs to be introduced inside the 
cell by artificial means to manifest its effect. The killing po-
tency and absence of cell binding activity make restrictocin a 
suitable molecule to be used as a toxin moiety of an immu-
notoxin [12-14]. Previously we have expressed restrictocin in 
E. coli and shown that the recombinant toxin is as active as 
the native protein [15]. We have also shown that recombinant 
restrictocin has low toxicity, and is poorly immunogenic when 
tested in mice [14]. We have earlier made active chemical 
conjugates with recombinant restrictocin targeted at the hu-
man transferrin receptor [14]. Here we report on the construc-
tion and characterization of TGFa-based chimeric toxins of 
restrictocin targeted at the human epidermal growth factor 
receptor. 
2. Materials and methods 
2.1. Cell lines and cell culture 
A431 (epidermoid carcinoma), A549 (lung carcinoma), K562 (er-
ythroleukemia) (all human) and L929, a mouse fibroblast cell line, 
were obtained from ATCC. All the cell lines were maintained in ex-
ponential growth in RPMI 1640 medium supplemented with 2 mM 
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glutamine and 10% fetal calf serum, at 37°C in a humidified atmo-
sphere containing 5% CO2. 
2.2. Construction of plasmids 
To construct pTGFa-restrictocin, plasmid pVC320, containing 
TGFa as a Ndel-Ndel insert, was digested with Ndel [16]. The puri-
fied insert was ligated into Ndel digested pRest, a T7 promoter based 
bacterial expression vector, that contains restrictocin as an Ndel-
EcoKl fragment. The clone so generated contained DNA coding for 
TGFa at the 5' end of restrictocin DNA. To construct pRestrictocin-
TGFa, restrictocin DNA was amplified by PCR from the plasmid 
pRest to create Ndel sites at both the ends of the fragment [15]. 
PCR was used to create Ndel and EcoRl recognition sites respectively 
at the 5' and 3' ends of the TGFa fragment, using pVC320 [16] as 
template. Amplified fragment of restrictocin was digested with Ndel 
while TGFa fragment was digested with Ndel and EcoRl. Both the 
fragments were ligated in E. coli expression vector pVexll, digested 
with Ndel and EcoRl. This gave rise to pRestrictocin-TGFa, contain-
ing DNA coding for TGFa at the 3' end of restrictocin. The correct 
clones were identified by restriction analysis and protein expression. 
E. coli strain DH5a was used for DNA manipulation. 
2.3. Expression and purification of chimeric toxins 
E. coli strain BL21 (XDE3) was used for protein expression. Cells 
were separately transformed with pTGFa-restrictocin or pRestricto-
cin-TGFa and grown in super broth containing 100 |Xg/ml of ampi-
cillin at 37°C with shaking. At an ODßoo of 2.0, the cells were induced 
with 1 mM IPTG, and 2 h later, they were harvested by centrifugation 
at 6000 rpm for 20 min. Inclusion bodies, isolated from the total cell 
pellet using the protocol described [17], were denatured in guanidine 
hydrochloride and reduced by dithioerythritol, followed by renatura-
tion in refolding buffer containing arginine and oxidized glutathione. 
Renatured material was dialyzed against 50 mM phosphate buffer 
(PB), pH 6.5, containing 100 mM urea and purified on a S-Sepharose 
column using an FPLC system (Pharmacia). The fusion proteins were 
purified to homogeneity by gel filtration chromatography on a TSK 
3000 column (LKB). 
2.4. Ribonucleolytic activity of chimeric toxins 
The ribonucleolytic activity of fusion proteins was assayed, in vitro, 
by measuring the inhibition of translation of endogenous globin 
mRNA of rabbit reticulocyte lysate in the presence of toxins. Rabbit 
reticulocyte lysate was prepared and the assay performed as described 
[18]. Incorporation of [3H]leucine was measured as a function of toxin 
concentration. 
2.5. Cytotoxicity and specificity of chimeric toxins 
Activity of fusion proteins was evaluated on human carcinomas by 
assaying protein synthesis, in the absence and presence of various 
concentrations of toxins. After 48 h of incubation, with the toxin, 
adherent cells (A431, A549) were washed twice with leucine free 
DMEM and pulsed for 2 h with 0.25 uCi of [3H]leucine. Suspension 
cells (K562) were directly labeled with 0.5 u.Ci of [3H]leucine for 2 h. 
The cells were harvested on a glass fiber filter and counted using a 
LKB ß-plate counter. 
Fig. 1. Schematic representation of chimeric toxins. In pTGFa-restrictocin, DNA encoding TGFa has been fused at the 5' end of restrictocin 
DNA, while in the case of pRestrictocin-TGFa, it has been fused at the 3' end of restrictocin DNA. Amino acids, as single letter codes, shown 
in bold uppercase letters are of restrictocin, while those shown in outlined uppercase represent amino acids of TGFa. Extra amino acids intro-
duced in the protein, because of the cloning strategy, are mentioned in lowercase letters. ORI: Bacterial origin of replication; F+: Bacterio-
phage origin of replication; AMP: ampicillin resistance gene; T7: T7 promoter. 
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2.6. Binding assay 
The binding of fusion proteins to EGF receptor was evaluated by 
estimating their ability to displace iodinated epidermal growth factor 
bound to A431 cells. EGF was iodinated using iodogen method [19]. 
In a 24 well plate, 40 000 cells were plated per well and left overnight 
at 37°C to adhere. Cells were washed twice with binding buffer 
(RPMI 1640 containing 2 mM glutamine, 25 mM HEPES pH 7.2 
and 0.1% BSA) and used for the assay. 
3. Results 
3.1. Construction and expression of chimeric toxins 
Plasmids pTGFoc-restrictocin and pRestrictocin-TGFa are 
T7 promoter based bacterial expression vectors, containing 
DNA encoding TGFcx cloned respectively at the 5' and 3' 
end of restrictocin DNA. Fig. 1 shows the schematic repre-
sentations of these constructs. The constructs were separately 
expressed in E. coli strain BL21 (1DE3), and in both cases, a 
protein of the expected molecular weight (22 kDa) was over-
expressed as seen in the total cell pellet (Fig. 2, lane 1). Both 
the fusion proteins accumulated in spheroplast, in the form of 
insoluble inclusion bodies (Fig. 2, lane 2). The proteins were 
purified from the inclusion bodies by a three step purification 
protocol. In the first step, recombinant protein was isolated by 
denaturation of purified inclusion bodies and renatured in 
vitro. After renaturation, in the second step, chimeric toxins 
were purified on a cation exchange column (Fig. 2, lane 3). 
Proteins at this stage were almost 90% pure. In the last step, 
protein from the cation exchange column was further purified 
on a gel filtration column to separate aggregated multimers of 
the fusion proteins from the monomeric units (Fig. 2, lane 4). 
For all subsequent studies, monomeric protein obtained from 
the gel filtration column was used. 
3.2. In vitro activity of chimeric toxins 
Earlier we have shown that recombinant restrictocin po-
tently inhibits protein synthesis in a rabbit reticulocyte based 
cell free translation assay system [15]. TGFa-containing chi-
meric toxins were also evaluated in vitro, for their translation 
inhibition activity. As shown in Fig. 3, both proteins effec-
tively inhibited translation of endogenous globin mRNA in 
the assay. Inhibition was dose dependent and the amount of 
protein required to decrease protein synthesis to half (ID50) 
was 0.15 and 0.40 nM for TGFa-restrictocin and restrictocin-
TGFoc respectively. TGFa-restrictocin and restrictocin-TGFa 
Fig. 2. Purification of chimeric toxins. A and B represent TGFa-re-
strictocin and restrictocin-TGFa respectively. A 12% reducing SDS-
polyacrylamide gel was run and stained with Coomassie blue. Lane 
1, total cell pellet; lane 2, inclusion bodies; lane 3, protein after S-
Sepharose column; lane 4, protein after gel filtration. Molecular 
weight markers are shown X 10~3 Da. 
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Fig. 3. Activity of chimeric toxins in cell free translation assay sys-
tem. Rabbit reticulocyte lysate was incubated with different concen-
trations of TGFa-restrictocin (•), restrictocin-TGFa (■), and re-
strictocin (O), for 1 h at 30°C, and proteins were precipitated with 
20% TCA. Precipitated material was collected on a glass fiber filter 
and counted on a beta counter for [3H]leucine incorporation. The 
concentration of toxin required to inhibit protein synthesis by 50% 
(ID50) was calculated by comparison with uninhibited protein sam-
ples. 
were respectively six-fold and 16-fold less active than recombi-
nant restrictocin, which had an ID50 of 0.025 nM in the same 
assay (Fig. 3). 
3.3. Cytotoxicity and specificity of chimeric toxins 
The cytotoxic potential of the two fusion proteins was eval-
uated on two target cell lines A431 and A549. The fusion 
proteins inhibited protein synthesis in target cells in a dose 
dependent manner (Fig. 4). Both restrictocin-TGFa and 
TGFa-restrictocin showed maximum activity on A431 cells, 
which express EGF receptor in excess, with ID50S of 1.66 nM 
and 4.16 nM respectively. Restrictocin-TGFa was found to be 
2.5-fold more active than TGFa-restrictocin (Table 1). On 
A549, a human lung carcinoma, restrictocin-TGFa showed 
activity similar to that on A431 but TGFa-restrictocin was 
found to have no cytotoxicity. On a EGFR negative cell line 
K562, both TGFa-restrictocin and restrictocin-TGFa were 
inactive. To check whether these chimeric toxins also recog-
nize EGFR across the species, cytotoxic effect of these toxins 
was evaluated on a mouse fibroblast cell line L929. Both pro-
teins had no cytotoxic effect on a murine cell line L929, as no 
inhibition of protein synthesis was observed even at a concen-
tration of 200 nM, indicating the specific binding of the pro-
teins to the human EGF receptor (Table 1). Restrictocin alone 
did not show any activity up to 115 nM (data not shown). 
Specificity of the chimeric toxins for the EGFR was checked 
by measuring their cytotoxic activity in the presence of free 
EGF. Excess of free EGF (1 uM) prevented the cytotoxic 
effect of fusion toxins (Fig. 4). 
3.4. Binding of chimeric toxins 
As TGFa-restrictocin and restrictocin-TGFa showed differ-
ential activity on target cell lines, their binding activities to 
EGF receptor were checked by measuring the ability of the 
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Fig. 4. Activity of chimeric toxins on A431 cell line. TGFa-restrictocin (circles) or restrictocin-TGFa (squares) was added to the cells in the ab-
sence (open symbols) or in the presence (closed symbols) of excess 1 u.M EGF for 48 h at 37°C. [3H]Leucine incorporation was measured as 
described. The results are calculated as percentage of total radioactivity incorporated in the cells incubated without chimeric toxin. 
two fusion proteins to compete with [125I]EGF for binding to 
the EGFR. As shown in Fig. 5, both proteins were found to 
be equally potent in their ability to bind to the EGF receptor. 
However, their binding activity was 50-fold lower than that of 
the EGF. 
4. Discussion 
EGFR has been used as a target in the past with PE and 
DT based chimeric toxins [8,16,20]. TGFa-PE40, a fusion 
protein in which TGFa is fused at the amino terminus of a 
truncated form of PE, has undergone clinical trials for the 
intravesical therapy of bladder cancer [21]. DAB38gEGF, 
which contains EGF fused at the carboxyl terminus of a trun-
cated form of DT, has shown potent cytotoxic activity on 
various target cell lines [8]. These studies show that a cyto-
toxic agent which targets the EGF receptor can be highly 
selective and effective for the treatment of carcinomas, char-
acterized by elevated EGF receptor expression. Previously we 
have demonstrated that recombinant restrictocin is poorly im-
munogenic and has low in vivo toxicity in mice [14]. It has 
also been used as a toxin component in the construction of 
immunotoxin [14]. In the present study we have explored the 
possibility of using restrictocin to construct chimeric toxin 
using TGFa as ligand. In the two fusion proteins made, the 
site of attachment of the ligand with respect to the toxin is 
different. TGFa-restrictocin and restrictocin-TGFa contain 
TGFa respectively at the amino and carboxyl ends of restric-
tocin. The constructs were expressed in E. coli and the pro-
teins were purified to homogeneity. Although TGFa-restric-
tocin had 2-fold higher in vitro ribonucleolytic activity than 
restrictocin-TGFa, and they both bound to the EGFR with 
equal affinities, yet on target cells restrictocin-TGFa was 
found to be more toxic compared to TGFa-restrictocin. It 
clearly indicates that the preferred site of ligand attachment 
on restrictocin is at its carboxyl terminus. The site of attach-
ment of the ligand in a chimeric toxin critically influences its 
cytotoxic potential. In DT based chimeric toxins, molecules 
where the ligand is attached at the carboxyl terminus are 
invariably more active than molecules where the ligand is 
present at the amino terminus [1]. In the case of PE, the ligand 
is attached at the amino terminus of the toxin, as the carboxyl 
terminus of the toxin contains an endoplasmic retention signal 
sequence and cannot be blocked [1]. 
Both chimeric toxins did not retain the full enzymatic ac-
tivity of restrictocin or the binding activity of the ligand. This 
could be due either to misfolding of one protein with respect 
to the other or to a steric hindrance posed by the additional 
protein. However, despite the reduction in enzymatic and 
binding activities of its components, the fusion proteins man-
ifested potent and specific cytotoxic activities on the target 
cells. 
The cytotoxic activity of an immunotoxin or chimeric toxin 
involves its binding to the target, intracellular processing, and 
translocation to the intracellular target [1]. All these steps are 
critical. As both restrictocin based chimeric toxins, TGFa-
restrictocin and restrictocin-TGFa bind EGFR with similar 
affinities, differences in their cytotoxic activities appear to be 
due to the differential intracellular processing and/or trans-
location. In this context, location of the binding ligand on 
Table 1 
Cytotoxic activity of TGFa-based chimeric toxins 
Cell line Origin ID50 (nM) 
Epidermoid carcinoma 
Lung carcinoma 
Erythroleukemia 
Mouse fibroblast 
TGFa-Restrictocin 
4.16 
> 40.00 
> 40.00 
> 200.00 
Restrictocin-TGFa 
1.66 
1.87 
> 40.00 
> 200.00 
A431 or A549 cells were seeded at a density of 5 X103 cells per well in 96 well plates, 16 h before the addition of toxin. K562 was seeded in 80%o 
leucine free DMEM containing 18% RPMI 1640 and 2% serum, and used immediately. Toxin was diluted in Dulbecco's PBS containing 0.2%> 
human serum albumin. ID50 is the amount of chimeric toxin required to decrease protein synthesis to 50%o of control, where no toxin has been 
added. 
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Fig. 5. Binding activity of chimeric toxins. 125I-labeled EGF, at a 
concentration of 1.5 ng per well, was added with various concentra-
tions of TGFcc-restrictocin (•), restrictocin-TGFa (■) and EGF (o) 
on A431 cells, in 0.2 ml of binding buffer. Cells were incubated for 
1 h at 4°C. At the end of incubation, cells were washed three times 
with binding buffer, and lysed with 10 mM Tris-HCl containing 
0.5% SDS and 1 mM EDTA. The bound ligand was counted in a 
gamma counter (LKB). 
restrictocin appears to be critical and a carboxyl terminal 
fusion appears to be tolerated better. 
In conclusion, we have demonstrated that it is possible to 
make restrictocin-based chimeric toxins directed at the human 
E G F receptor. Chimeric toxins containing ligand at the car-
boxyl terminus of restrictocin had better cytotoxic activity. 
The molecules generated in the current study contain toxin 
and ligand fused in tandem without any linkers. Modification 
of these proteins by introducing a spacer between the two 
components may improve the folding of the molecule, thereby 
further improving their biological activities. As restrictocin 
has already been shown to have low in vivo toxicity and 
immunogenicity, it holds potential for being used as a toxin 
moiety in targeted therapy in the future. 
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